Halozyme Therapeutics prices $1.3 billion convertible notes

* Halozyme Therapeutics (HALO [https://seekingalpha.com/symbol/HALO]) priced [https://seekingalpha.com/pr/20298440-halozyme-therapeutics-inc-announces-pricing-of-private-offering-of-650-million-of-convertible] $650 million aggregate principal amount of 0% convertible senior notes due 2031 and $650 million aggregate principal amount of 0.875% convertible senior notes due 2032.
* The company granted a 13-day option to the initial purchasers to purchase up to an additional $100 million aggregate principal amount of the 2031 notes and up to an additional $100 million aggregate principal amount of the 2032 notes.
* The company expects to close the offering on November 12, 2025.
* Net proceeds will be ~$1.274B (or ~$1.47B if the initial purchasers exercise their option)
* The company expects to use ~$182.7M of the net proceeds of the offering to fund capped call transaction and ~$1.020 billion to enter into privately negotiated agreements with certain holders of its outstanding 0.25% convertible senior notes due 2027, and the remainder for general corporate purposes.

MORE ON HALOZYME THERAPEUTICS

* Halozyme Therapeutics, Inc. (HALO) Q3 2025 Earnings Call Transcript [https://seekingalpha.com/article/4837160-halozyme-therapeutics-inc-halo-q3-2025-earnings-call-transcript]
* Halozyme Therapeutics, Inc. 2025 Q3 - Results - Earnings Call Presentation [https://seekingalpha.com/article/4837072-halozyme-therapeutics-inc-2025-q3-results-earnings-call-presentation]
* Halozyme Just Bought Its Next Decade Of Growth [https://seekingalpha.com/article/4832604-halozyme-just-bought-its-next-decade-of-growth]
* Halozyme Therapeutics announces proposed offering of $650M of convertible senior notes due 2031 and 2032 [https://seekingalpha.com/news/4516460-halozyme-therapeutics-announces-proposed-offering-of-650m-of-convertible-senior-notes-due]
* Halozyme raises 2025 guidance to $1.3B–$1.375B revenue driven by royalty momentum and expands with Elektrofi acquisition [https://seekingalpha.com/news/4513809-halozyme-raises-2025-guidance-to-1_3b-1_375b-revenue-driven-by-royalty-momentum-and-expands]